title: Doxorubicin/gold-loaded core/shell nanoparticles for combination therapy to treat cancer through the enhanced tumor targeting.
abstract: A combination therapy consisting of radiotherapy and chemotherapy is performed using the core/shell nanoparticles (NPs) containing gold NPs and doxorubicin (DOX). Gold NPs in the core/shell NPs were utilized as a radiosensitizer. To examine the morphology and size distribution of the core/shell NPs, transmittance electron microscopy and dynamic light scattering were used. The in vitro release behavior, cellular uptake and toxicity were also observed to verify the functionality of the core/shell NPs as a nanocarrier. To demonstrate the advantage of the core/shell NPs over traditional gold NPs reported in the combination therapy, we evaluated the accumulation behavior of the core/shell NPs at the tumor site using the biodistribution. Antitumor efficacy was observed with and without radiation to evaluate the role of gold NPs as a radiosensitizer.
authors.affiliation: College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea.
authors.forename: Kyungim
authors.initials: K
authors.lastname: Kim
authors.affiliation: College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea.
authors.forename: Keun Sang
authors.initials: KS
authors.lastname: Oh
authors.affiliation: College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea.
authors.forename: Dal Yong
authors.initials: DY
authors.lastname: Park
authors.affiliation: College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea.
authors.forename: Jae Young
authors.initials: JY
authors.lastname: Lee
authors.affiliation: Center for Theragnosis, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Sungbuk-gu, Seoul 136-791, Republic of Korea; Department of Otolaryngology, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea.
authors.forename: Beom Suk
authors.initials: BS
authors.lastname: Lee
authors.affiliation: Center for Theragnosis, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Sungbuk-gu, Seoul 136-791, Republic of Korea.
authors.forename: In San
authors.initials: IS
authors.lastname: Kim
authors.affiliation: Center for Theragnosis, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Sungbuk-gu, Seoul 136-791, Republic of Korea.
authors.forename: Kwangmeyung
authors.initials: K
authors.lastname: Kim
authors.affiliation: Center for Theragnosis, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Sungbuk-gu, Seoul 136-791, Republic of Korea.
authors.forename: Ick Chan
authors.initials: IC
authors.lastname: Kwon
authors.affiliation: Center for Theragnosis, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Sungbuk-gu, Seoul 136-791, Republic of Korea; Department of Otolaryngology, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea.
authors.forename: Yoon Kim
authors.initials: YK
authors.lastname: Sang
authors.affiliation: College of Pharmacy, Korea University, 2511 Sejongro, Sejong 339-700, Republic of Korea. Electronic address: shyuk@korea.ac.kr.
authors.forename: Soon Hong
authors.initials: SH
authors.lastname: Yuk
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D059248:Chemoradiotherapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D006046:Gold / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D053768:Metal Nanoparticles / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014018:Tissue Distribution
chemical_list: D000903:Antibiotics, Antineoplastic; D011838:Radiation-Sensitizing Agents; D006046:Gold; D004317:Doxorubicin
keywords: Combination therapy; Core/shell nanoparticles; Doxorubicin; Gold nanoparticles; Radiotherapy